Table 3.

Baseline and final non-mineral-related end points

CharacteristicsCholecalciferolDoxercalciferolBetween-Treatment Group Pa
Baseline (n = 22)Final (n = 20)Pre-Post PBaseline (n = 25)Final (n = 20)Pre-Post P
Home systolic BP145 ± 20128 ± 340.17142 ± 15120 ± 470.070.48
Home diastolic BP75 ± 1464 ± 120.1175 ± 1167 ± 260.250.97
Standardized systolic BP139 ± 17140 ± 200.42141 ± 19137 ± 200.630.29
Standardized diastolic BP74 ± 1173 ± 160.8177 ± 1374 ± 150.430.26
Urine albumin/creatinine ratio, μg/mg964 ± 1059669 ± 6670.36755 ± 1230438 ± 8600.10.47
  • a By repeated-measures two-way ANOVA with visit (baseline and end point), drug, and their interaction as factors.